Coherus Biosciences Inc (NASDAQ: CHRS)’s stock price has gone rise by 6.47 in comparison to its previous close of 1.70, however, the company has experienced a 32.12% increase in its stock price over the last five trading days. benzinga.com reported 2024-12-03 that On Tuesday, Coherus BioSciences, Inc. CHRS entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for up to $558.4 million.
Is It Worth Investing in Coherus Biosciences Inc (NASDAQ: CHRS) Right Now?
The stock has a 36-month beta value of 0.86. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CHRS is 110.58M, and at present, short sellers hold a 29.88% of that float. On December 09, 2024, the average trading volume of CHRS was 5.08M shares.
CHRS’s Market Performance
CHRS’s stock has seen a 32.12% increase for the week, with a 120.73% rise in the past month and a 33.09% gain in the past quarter. The volatility ratio for the week is 22.94%, and the volatility levels for the past 30 days are at 16.67% for Coherus Biosciences Inc The simple moving average for the past 20 days is 53.58% for CHRS’s stock, with a 13.35% simple moving average for the past 200 days.
Analysts’ Opinion of CHRS
Many brokerage firms have already submitted their reports for CHRS stocks, with UBS repeating the rating for CHRS by listing it as a “Neutral.” The predicted price for CHRS in the upcoming period, according to UBS is $1.50 based on the research report published on August 16, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CHRS reach a price target of $11. The rating they have provided for CHRS stocks is “Outperform” according to the report published on November 17th, 2023.
CHRS Trading at 81.60% from the 50-Day Moving Average
After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.08% of loss for the given period.
Volatility was left at 16.67%, however, over the last 30 days, the volatility rate increased by 22.94%, as shares surge +120.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +71.43% upper at present.
During the last 5 trading sessions, CHRS rose by +31.39%, which changed the moving average for the period of 200-days by -30.23% in comparison to the 20-day moving average, which settled at $1.1780. In addition, Coherus Biosciences Inc saw -45.65% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CHRS
Current profitability levels for the company are sitting at:
- -0.43 for the present operating margin
- 0.43 for the gross margin
The net margin for Coherus Biosciences Inc stands at -0.0. The total capital return value is set at -0.63.
Based on Coherus Biosciences Inc (CHRS), the company’s capital structure generated 1.61 points at debt to capital in total, while cash flow to debt ratio is standing at -0.27. The debt to equity ratio resting at -2.63. The interest coverage ratio of the stock is -4.04.
Currently, EBITDA for the company is -193.94 million with net debt to EBITDA at -1.23. When we switch over and look at the enterprise to sales, we see a ratio of 1.13. The receivables turnover for the company is 1.53for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
To sum up, Coherus Biosciences Inc (CHRS) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
